Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature.
A 69-year-old man with advanced prostate cancer was receiving antiandrogen therapy (bicalutamide [Casodex]). He developed dyspnea, peripheral eosinophilia and bilateral pulmonary interstitial infiltrates. Transbronchial biopsy confirmed pulmonary eosinophilia. Withdrawal of bicalutamide and initiation of steroid therapy resulted in clinical improvement.
Wong
P W
PW
Department of Medicine, Lenox Hill Hospital, New York, USA.
Macris
N
N
DiFabrizio
L
L
Seriff
N S
NS
D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects*; D000813:Anilides / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001706:Biopsy; D004417:Dyspnea / Q000139:chemically induced; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011657:Pulmonary Eosinophilia / Q000139:chemically induced* / Q000188:drug therapy; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D000893:Anti-Inflammatory Agents; D018931:Antineoplastic Agents, Hormonal; D005938:Glucocorticoids; D009570:Nitriles; D014105:Tosyl Compounds; D008776:Methylprednisolone Hemisuccinate; C053541:bicalutamide